Free Trial
NASDAQ:KZR

Kezar Life Sciences (KZR) Stock Price, News & Analysis

Kezar Life Sciences logo
$6.86 +0.29 (+4.41%)
As of 01/3/2025 05:45 PM Eastern

About Kezar Life Sciences Stock (NASDAQ:KZR)

Key Stats

Today's Range
$6.50
$6.93
50-Day Range
$6.29
$8.19
52-Week Range
$5.20
$11.35
Volume
25,172 shs
Average Volume
42,136 shs
Market Capitalization
$50.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.50
Consensus Rating
Hold

Company Overview

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Kezar Life Sciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
70th Percentile Overall Score

KZR MarketRank™: 

Kezar Life Sciences scored higher than 70% of companies evaluated by MarketBeat, and ranked 330th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Kezar Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Kezar Life Sciences has only been the subject of 3 research reports in the past 90 days.

  • Read more about Kezar Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Kezar Life Sciences are expected to decrease in the coming year, from ($5.17) to ($8.31) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Kezar Life Sciences is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Kezar Life Sciences is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Kezar Life Sciences has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.76% of the float of Kezar Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Kezar Life Sciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Kezar Life Sciences has recently decreased by 54.57%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Kezar Life Sciences does not currently pay a dividend.

  • Dividend Growth

    Kezar Life Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.76% of the float of Kezar Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Kezar Life Sciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Kezar Life Sciences has recently decreased by 54.57%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Kezar Life Sciences insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 9.30% of the stock of Kezar Life Sciences is held by insiders.

    • Percentage Held by Institutions

      67.90% of the stock of Kezar Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Kezar Life Sciences' insider trading history.
    Receive KZR Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

    KZR Stock News Headlines

    Kezar Life Sciences price target lowered to $9 from $11 at Wells Fargo
    URGENT: This Altcoin Opportunity Won’t Wait – Act Now
    Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
    Kezar Life Sciences (KZR) Receives a Hold from H.C. Wainwright
    Kezar struck again with second FDA hold
    Kezar Life Sciences (KZR) Receives a Buy from TD Cowen
    See More Headlines

    KZR Stock Analysis - Frequently Asked Questions

    Kezar Life Sciences' stock was trading at $6.72 at the beginning of 2025. Since then, KZR stock has increased by 2.1% and is now trading at $6.86.
    View the best growth stocks for 2025 here
    .

    Kezar Life Sciences, Inc. (NASDAQ:KZR) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($2.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.03) by $0.25.

    Kezar Life Sciences shares reverse split before market open on Wednesday, October 30th 2024. The 1-10 reverse split was announced on Monday, October 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

    Kezar Life Sciences (KZR) raised $70 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

    Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
    Compare Top Brokerages Here.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Kezar Life Sciences investors own include Predictive Oncology (POAI), Ford Motor (F), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Bank of America (BAC), Abbott Laboratories (ABT) and Zomedica (ZOM).

    Company Calendar

    Last Earnings
    11/12/2024
    Today
    1/05/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:KZR
    Fax
    N/A
    Employees
    60
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $39.50
    High Stock Price Target
    $70.00
    Low Stock Price Target
    $9.00
    Potential Upside/Downside
    +475.8%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.00
    Research Coverage
    3 Analysts

    Profitability

    Net Income
    $-101,870,000.00
    Pretax Margin
    -1,408.11%

    Debt

    Sales & Book Value

    Annual Sales
    $7 million
    Book Value
    $25.80 per share

    Miscellaneous

    Free Float
    6,617,000
    Market Cap
    $50.05 million
    Optionable
    Not Optionable
    Beta
    0.21
    A Beginner's Guide to Investing in Cannabis Cover

    Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

    Get This Free Report

    This page (NASDAQ:KZR) was last updated on 1/5/2025 by MarketBeat.com Staff
    From Our Partners